Decreased Serum Osteocalcin is an Independent Risk Factor for Metabolic Dysfunction-Associated Fatty Liver Disease in Type 2 Diabetes

References

• Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007;130(3):456–469. doi:10.1016/j.cell.2007.05.047
   PubMed Web of Science ®Google Scholar
• Diegel CR, Hann S, Ayturk UM, et al. An osteocalcin-deficient mouse strain without endocrine abnormalities. PLoS Genet. 2020;16(5):e1008361. doi:10.1371/journal.pgen.1008361
   Web of Science ®Google Scholar
• Moriishi T, Ozasa R, Ishimoto T, et al. Osteocalcin is necessary for the alignment of apatite crystallites, but not glucose metabolism, testosterone synthesis, or muscle mass. PLoS Genet. 2020;16(5):e1008586. doi:10.1371/journal.pgen.1008586
   Web of Science ®Google Scholar
• Guo H, Wang C, Jiang B, et al. Association of insulin resistance and β-cell function with bone turnover biomarkers in dysglycemia patients. Front Endocrinol. 2021;12:554604. doi:10.3389/fendo.2021.554604
   PubMed Web of Science ®Google Scholar
• Liu X, Yeap BB, Brock KE, et al. Associations of osteocalcin forms with metabolic syndrome and its individual components in older men: the health in men study. J Clin Endocrinol Metab. 2021;106(9):e3506–e3518. doi:10.1210/clinem/dgab358
   Web of Science ®Google Scholar
• Razny U, Fedak D, Kiec-Wilk B, et al. Carboxylated and undercarboxylated osteocalcin in metabolic complications of human obesity and prediabetes. Diabetes Metab Res Rev. 2017;33(3):e2862. doi:10.1002/dmrr.2862
   Web of Science ®Google Scholar
• Zeng H, Ge J, Xu W, et al. Type 2 diabetes is causally associated with reduced serum osteocalcin: a genomewide association and mendelian randomization study. J Bone Miner Res. 2021;36(9):1694–1707. doi:10.1002/jbmr.4330
   Web of Science ®Google Scholar
• Saleem U, Mosley TH, Kullo IJ. Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of metabolic syndrome. Arterioscler Thromb Vasc Biol. 2010;30(7):1474–1478. doi:10.1161/atvbaha.110.204859
   Web of Science ®Google Scholar
• Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi:10.1016/j.jhep.2020.03.039
   PubMed Web of Science ®Google Scholar
• Méndez-Sánchez N, Bugianesi E, Gish RG, et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7(5):388–390. doi:10.1016/s2468-1253(22)00062-0
   PubMed Web of Science ®Google Scholar
• Xia M, Rong S, Zhu X, et al. Osteocalcin and non-alcoholic fatty liver disease: lessons from two population-based cohorts and animal models. J Bone Miner Res. 2021;36(4):712–728. doi:10.1002/jbmr.4227
   Web of Science ®Google Scholar
• Luo YQ, Ma XJ, Hao YP, et al. Inverse relationship between serum osteocalcin levels and nonalcoholic fatty liver disease in postmenopausal Chinese women with normal blood glucose levels. Acta Pharmacol Sin. 2015;36(12):1497–1502. doi:10.1038/aps.2015.81
   Web of Science ®Google Scholar
• Liu JJ, Chen YY, Mo ZN, et al. Relationship between serum osteocalcin levels and non-alcoholic fatty liver disease in adult males, South China. Int J Mol Sci. 2013;14(10):19782–19791. doi:10.3390/ijms141019782
   Web of Science ®Google Scholar
• Deng H, Dai Y, Lu H, Li SS, Gao L, Zhu DL. Analysis of the correlation between non-alcoholic fatty liver disease and bone metabolism indicators in healthy middle-aged men. Eur Rev Med Pharmacol Sci. 2018;22(5):1457–1462. doi:10.26355/eurrev_201803_14493
   Web of Science ®Google Scholar
• Dou J, Ma X, Fang Q, et al. Relationship between serum osteocalcin levels and non-alcoholic fatty liver disease in Chinese men. Clin Exp Pharmacol Physiol. 2013;40(4):282–288. doi:10.1111/1440-1681.12063
   Web of Science ®Google Scholar
• Aller R, Castrillon JL, de Luis DA, et al. Relation of osteocalcin with insulin resistance and histopathological changes of non alcoholic fatty liver disease. Ann Hepatol. 2011;10(1):50–55. doi:10.1016/S1665-2681(19)31587-X
   Web of Science ®Google Scholar
• Yilmaz Y, Kurt R, Eren F, Imeryuz N. Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: association with ballooning degeneration. Scand J Clin Lab Invest. 2011;71(8):631–636. doi:10.3109/00365513.2011.604427
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801. doi:10.1016/j.jhep.2019.06.021
   PubMed Web of Science ®Google Scholar
• Wu Y, Zheng Q, Zou B, et al. The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis. Hepatol Int. 2020;14(2):259–269. doi:10.1007/s12072-020-10023-3
   PubMed Web of Science ®Google Scholar
• Muzurović E, Peng CC, Belanger MJ, Sanoudou D, Mikhailidis DP, Mantzoros CS. Nonalcoholic fatty liver disease and cardiovascular disease: a review of shared cardiometabolic risk factors. Hypertension. 2022;79(7):1319–1326. doi:10.1161/hypertensionaha.122.17982
   PubMed Web of Science ®Google Scholar
• Wild SH, Walker JJ, Morling JR, et al. Cardiovascular disease, cancer, and mortality among people with type 2 diabetes and alcoholic or nonalcoholic fatty liver disease hospital admission. Diabetes Care. 2018;41(2):341–347. doi:10.2337/dc17-1590
   PubMed Web of Science ®Google Scholar
• Wang N, Wang Y, Chen X, et al. Bone turnover markers and probable advanced nonalcoholic fatty liver disease in middle-aged and elderly men and postmenopausal women with type 2 diabetes. Front Endocrinol. 2019;10:926. doi:10.3389/fendo.2019.00926
   Web of Science ®Google Scholar
• Zhu X, Yan H, Chang X, et al. Association between non-alcoholic fatty liver disease-associated hepatic fibrosis and bone mineral density in postmenopausal women with type 2 diabetes or impaired glucose regulation. BMJ Open Diabetes Res Care. 2020;8(1). doi:10.1136/bmjdrc-2019-000999
   Web of Science ®Google Scholar
• Zhang ZH, Ke JF, Lu JX, Liu Y, Wang AP, Li LX. Serum retinol-binding protein levels are associated with nonalcoholic fatty liver disease in Chinese patients with type 2 diabetes: a real-world study. Diabetes Metab J. 2021;46(1):129–139. doi:10.4093/dmj.2020.0222
   Web of Science ®Google Scholar
• Li TT, Wang AP, Lu JX, et al. Prevalence and clinical characteristics of non-alcoholic fatty liver disease in newly diagnosed patients with ketosis-onset diabetes. Diabetes Metab. 2018;44(5):437–443. doi:10.1016/j.diabet.2018.03.002
   Web of Science ®Google Scholar
• Zhao CC, Wang AP, Li LX, et al. Urine uric acid excretion is associated with nonalcoholic fatty liver disease in patients with type 2 diabetes. J Diabetes Complications. 2016;30(6):1074–1080. doi:10.1016/j.jdiacomp.2016.04.017
   Web of Science ®Google Scholar
• Li L, Yu H, Zhu J, et al. The combination of carotid and lower extremity ultrasonography increases the detection of atherosclerosis in type 2 diabetes patients. J Diabetes Complications. 2012;26(1):23–28. doi:10.1016/j.jdiacomp.2011.11.006
   Web of Science ®Google Scholar
• Li LX, Zhao CC, Ren Y, et al. Prevalence and clinical characteristics of carotid atherosclerosis in newly diagnosed patients with ketosis-onset diabetes: a cross-sectional study. Cardiovasc Diabetol. 2013;12:18. doi:10.1186/1475-2840-12-18
   PubMed Web of Science ®Google Scholar
• Li MF, Ren Y, Zhao CC, et al. Prevalence and clinical characteristics of lower limb atherosclerotic lesions in newly diagnosed patients with ketosis-onset diabetes: a cross-sectional study. Diabetol Metab Syndr. 2014;6:71. doi:10.1186/1758-5996-6-71
   PubMed Web of Science ®Google Scholar
• Li LX, Lu JX, Shuai HP, et al. Decreased urine uric acid excretion is associated with diabetic retinopathy but not with lower limb atherosclerosis in hospitalized patients with type 2 diabetes. Atherosclerosis. 2015;242(1):13–18. doi:10.1016/j.atherosclerosis.2015.06.051
   Web of Science ®Google Scholar
• Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487–1495. doi:10.2337/diacare.27.6.1487
   PubMed Web of Science ®Google Scholar
• Hou XH, Zhu YX, Lu HJ, et al. Non-alcoholic fatty liver disease’s prevalence and impact on alanine aminotransferase associated with metabolic syndrome in the Chinese. J Gastroenterol Hepatol. 2011;26(4):722–730. doi:10.1111/j.1440-1746.2010.06509.x
   Web of Science ®Google Scholar
• Wang JW, Jin CH, Ke JF, et al. Serum iron is closely associated with metabolic dysfunction-associated fatty liver disease in type 2 diabetes: a real-world study. Front Endocrinol. 2022;13:942412. doi:10.3389/fendo.2022.942412
   PubMedGoogle Scholar
• Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD. Clin Gastroenterol Hepatol. 2021;19(10):2172–2181.e6. doi:10.1016/j.cgh.2021.05.029
   PubMed Web of Science ®Google Scholar
• Lin S, Huang J, Wang M, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int. 2020;40(9):2082–2089. doi:10.1111/liv.14548
   PubMed Web of Science ®Google Scholar
• Wong VW, Wong GL, Woo J, et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease. Clin Gastroenterol Hepatol. 2021;19(10):2161–2171.e5. doi:10.1016/j.cgh.2020.10.046
   PubMed Web of Science ®Google Scholar
• Han E, Kim MK, Jang BK, Kim HS. Albuminuria is associated with steatosis burden in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Diabetes Metab J. 2021;45(5):698–707. doi:10.4093/dmj.2020.0118
   Web of Science ®Google Scholar
• Shi R, Lin C, Hong Y, et al. Free triiodothyronine is independently associated with nonalcoholic fatty liver disease in hospitalized type 2 diabetes mellitus patients. Biomed Res Int. 2021;2021:8868339. doi:10.1155/2021/8868339
   Web of Science ®Google Scholar
• Williamson RM, Price JF, Glancy S, et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care. 2011;34(5):1139–1144. doi:10.2337/dc10-2229
   PubMed Web of Science ®Google Scholar
• Lascar N, Brown J, Pattison H, Barnett AH, Bailey CJ, Bellary S. Type 2 diabetes in adolescents and young adults. Lancet Diabetes Endocrinol. 2018;6(1):69–80. doi:10.1016/s2213-8587(17)30186-9
   PubMed Web of Science ®Google Scholar
• Mukai S, Mizokami A, Otani T, et al. Adipocyte-specific GPRC6A ablation promotes diet-induced obesity by inhibiting lipolysis. J Biol Chem. 2021;296:100274. doi:10.1016/j.jbc.2021.100274
   PubMed Web of Science ®Google Scholar
• Bilotta FL, Arcidiacono B, Messineo S, et al. Insulin and osteocalcin: further evidence for a mutual cross-talk. Endocrine. 2018;59(3):622–632. doi:10.1007/s12020-017-1396-0
   PubMed Web of Science ®Google Scholar
• Newton KP, Lavine JE, Wilson L, et al. Alanine aminotransferase and gamma-glutamyl transpeptidase predict histologic improvement in pediatric nonalcoholic steatohepatitis. Hepatology. 2021;73(3):937–951. doi:10.1002/hep.31317
   PubMed Web of Science ®Google Scholar
• Roberts SK, Majeed A, Glenister K, et al. Prevalence of non-alcoholic fatty liver disease in regional Victoria: a prospective population-based study. Med J Aust. 2021;215(2):77–82. doi:10.5694/mja2.51096
   Web of Science ®Google Scholar
• Amin S, El Amrousy D, Elrifaey S, Gamal R, Hodeib H. Serum osteocalcin levels in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2018;66(1):117–121. doi:10.1097/mpg.0000000000001768
   PubMed Web of Science ®Google Scholar
• Sinn DH, Gwak GY, Rhee SY, et al. Association between serum osteocalcin levels and non-alcoholic fatty liver disease in women. Digestion. 2015;91(2):150–157. doi:10.1159/000369789
   Web of Science ®Google Scholar
• El Amrousy D, El-Afify D. Osteocalcin and osteoprotegerin levels and their relationship with adipokines and proinflammatory cytokines in children with nonalcoholic fatty liver disease. Cytokine. 2020;135:155215. doi:10.1016/j.cyto.2020.155215
   Web of Science ®Google Scholar
• Luger M, Kruschitz R, Kienbacher C, et al. Prevalence of liver fibrosis and its association with non-invasive fibrosis and metabolic markers in morbidly obese patients with vitamin D deficiency. Obes Surg. 2016;26(10):2425–2432. doi:10.1007/s11695-016-2123-2
   Web of Science ®Google Scholar
• Gupte AA, Sabek OM, Fraga D, et al. Osteocalcin protects against nonalcoholic steatohepatitis in a mouse model of metabolic syndrome. Endocrinology. 2014;155(12):4697–4705. doi:10.1210/en.2014-1430
   PubMed Web of Science ®Google Scholar
• Lim S, Kim JW, Targher G. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab. 2021;32(7):500–514. doi:10.1016/j.tem.2021.04.008
   PubMed Web of Science ®Google Scholar
• Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of insulin resistance in MAFLD. Int J Mol Sci. 2021;22(8):4156. doi:10.3390/ijms22084156
   PubMed Web of Science ®Google Scholar
• Torre P, Motta BM, Sciorio R, Masarone M, Persico M. Inflammation and fibrogenesis in MAFLD: role of the hepatic immune system. Front Med. 2021;8:781567. doi:10.3389/fmed.2021.781567
   Web of Science ®Google Scholar
• Kanazawa I, Tanaka S, Sugimoto T. The association between osteocalcin and chronic inflammation in patients with type 2 diabetes mellitus. Calcif Tissue Int. 2018;103(6):599–605. doi:10.1007/s00223-018-0460-y
   Web of Science ®Google Scholar
• Mao H, Li L, Fan Q, et al. Endothelium-specific depletion of LRP1 improves glucose homeostasis through inducing osteocalcin. Nat Commun. 2021;12(1):5296. doi:10.1038/s41467-021-25673-6
   Web of Science ®Google Scholar
• Guedes JAC, Esteves JV, Morais MR, Zorn TM, Furuya DT. Osteocalcin improves insulin resistance and inflammation in obese mice: participation of white adipose tissue and bone. Bone. 2018;115:68–82. doi:10.1016/j.bone.2017.11.020
   Web of Science ®Google Scholar